Project UpdateApr 28, 2026, 06:02 AM
EUDA Partner Shenzhen Inno Gets Shenzhen R&D Program Approval, $434K Funding
AI Summary
EUDA Health Holdings Ltd announced that its partner, Shenzhen Inno Immune Co., Ltd., received official approval under the 2025 Shenzhen Key Industry R&D Program. This government initiative is expected to provide funding of up to approximately US$434,688 to Shenzhen Inno for its "Key Technology Development of TCR-T Therapy for Solid Tumors" project, scheduled from January 1, 2026, to December 31, 2028. EUDA holds non-exclusive distribution rights to market and sell selected immunotherapies from Shenzhen Inno to customers in Malaysia. This development aligns with EUDA's strategy to expand access to advanced treatment modalities.
Key Highlights
- Shenzhen Inno received approval for 2025 Shenzhen Key Industry R&D Program.
- Project "TCR-T Therapy for Solid Tumors" to run from Jan 1, 2026, to Dec 31, 2028.
- Expected government funding of up to approximately $434,688 for Shenzhen Inno.
- EUDA holds non-exclusive rights to market Shenzhen Inno immunotherapies in Malaysia.
- Project focuses on TCR-T cell therapies targeting solid tumors.
Price Impact
More from EUDA